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Molecular Biology and Pathophysiology of
APC Resistance: Current Insights and
Clinical lmplications
JAN ROSING, Ph.D,  H.  COENRAAD HEMKER, Ph.D. ,  ANd
GUIDO TANS, Ph.D.
ABSTRACT APC resistance is often associated with
the occurrence of a single point mutation in factor V
(factor V".,u",) at a predominant cleavage site for the
natural anticoagulant, activated protein C (APC). In
this article we will discuss the effects of this mutation
(Argso0-6rn) on the down-regulation of factor Va
cofactor activity and on thrombin formation by APC
in model systems and in plasma. Our studies on the
effects of APC on thrombin formation in plasma re-
sulted in the development of a new method for the
screening of APC resistance that is based on mea-
surement of the effect of APC on the endogenous
thrombin potential (the time integral of thrombin
generated in clotting plasma). It appeared that sensi-
tivities for APC determined via this method were
considerably affected by the use of oral contracep-
tives (OC) and that women who use OC become ac-
quired APC resistant. The fact that acquired APC re-
sistance in women who use third-generation OC was
more pronounced than in users of second-generation
OC may explain the further increased risk for yenous
thrombosis associated with the use of third-genera-
tion OC.
Keywords: APC resistance, factor Vr,"ia"r, oral
contraceptives, venous thrombosis
Some 20 yeirrs ago it was recognizedthat the acti-
vated form of the plasma protein protein C, called APC,
is a serine protease that down-regulates thrombin forma-
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tion via limited proteolysis of factor Va.1,2 Soon after-
wards, it was reported that efficient inactivation of factor
Va by APC required the presence of negatively charged
phospholipids3{ and another vitamin K-dependent plasma
protein, protein S.4'5,7,8
The protein C pathway presently attracts much at-
tention of clinical and research laboratories. This is due
to the fact that in 1993 Bjrirn Dahlbiicke discovered a
new risk factor for familial venous thrombosis that is
characterized by inherited resistance to APC. About 1
year later it was reportedlo-13 that APC resistance is
caused by a single point mutation in the factor V gene
that results in the replacement of an amino acid at a pre-
dominant cleavage site for APC.
In this article we will discuss the effects of this mu-
tation on APC-catalyzed factor Va activation in model
systems and on the down-regulation of thrombin forma-
tion by APC in plasma. These studies have led to the de-
velopment of new methods for the screening of heredi-
tary and acquired APC resistance.
INACTIVATION OF FACTOR Va AND
FACTOR Vd..,'., lN MODEL SYSTEMS
Factor Va, the protein cofactor of the prothrombin-
activating complex, is a heterodimer that consists of a
heavy and a light chain held together by a single calcium
ion. In 1994 the group of Mannla reported that APC can
cleave three peptide bonds in the heavy chain of human
factor Va, which are located at positions Arg:00, Argsoo,
and Argato Gig. 1). Sequence analysis of the factor V
gene has shown that in APC-resistant individuals the
arginine at position 506 is replaced by glutamine.l0-i3 To
get more insight into the consequences of this mutation,
several laboratoriesls-le have purified factor Va from ho-
mozygous APC-resistant individuals (factor V,_.,a"n) and
compared its sensitivity for APC with that of normal fac-
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FlG. 1, APC cleavage sites in human factor Va. In factor
Vdr"io"n,Argso0 |a replaced by Gln.
tor Va in model systems containing purified proteins and
artificial phospholipid vesicles.
Figure 2 shows that normal factor Va is inactivated
by APC via a biphasic reaction that consists of a rapid
phase that yields a reaction intermediate that retains ap-
proximately 40Vo of the cofactor activity of native Va
and that is subsequently fully inactivated via a second,
slow reaction.lT Factor Vur",o"n is inactivated via a slow
monophasic reaction, the initial rate of which is some
2O-fold lower than that of normal Va. Detailed kinetic
analysis showed that inactivation of factor Var",u"n Pro-
ceeds at arcte that is approximately similar to that of the
second phase of normal factor Va inactivation.lT
Gel electrophoretic analysis of time courses of in-
activation of factor Va and factor Var"ru"ntz indicated that
the rapid phase of inactivation of normal factor Va is as-
sociated with cleavage at Angs06 and that inactivation is
completed via cleavage at Arg3o0. Factor Vur",u"n it
slowly but fully inactivated via a single peptide bond
cleavage at .A19:06.
100
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FlG. 2. Inactivation of factor Va and factor Va."'o"n by APC.
Time courses of inactivation of 0.3 nM factor Va (A) and 0'3 nM
factor Va.",o"n (r) by 1.5 nM APC were determined in the pres-
ence of 25 pM dioleoylphosphatidylserine/dioleoyl phosphatidyl-
chol ine (10/90, M/M) vesicles in 25 mM Hepes (pH 7.5), 175 mM
NaCl, and 3 mM CaCl, Data from Nicolaes s1 slrz (lsprinted with
permission)
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It is interesting to note that the heavy chain frag-
ments formed after cleavage at Argso6 remain associated
and that factor Va cleaved at Argso0 is still active as a co-
factor in prothrombin activation.lT This reaction inter-
mediate has considerably less affinity for factor Xa and
requires approximately 50 times more factor Xa for the
expression of cofactor activity in prothrombin activation
than native factor Va. As a consequence, factor Va cleaved
at Args06 can express variable residual cofactor activity
in prothrombin activation depending upon the amount of
factor Xa present.
Based on these observations we proposedtz that
normal factor Va can be inactivated by APC via two
pathways (Fig. 3), the predominant one being pathway
1, which involves rapid cleavage at Argso6 and formation
of a factor Va intermediate that still has cofactor activity
in prothrombin activation, which is subsequently fully
inactivated by slow cleavage at .4193o6. The latter peptide
bond can be cleaved also directly in factor Va. This is a
slow reaction that yields a form of factor Va with negli-
gible cofactor activity in prothrombin activation. Due to
the mutation at Argsoo, pathway I cannot occur in factor
V&L"id"n, which as a consequence can only be slowly in-
activated via pathw aY 2.
It should be emphasized that this is a model for fac-
tor Va inactivation by APC alone. However, it has been
known for many years that the activity of the protein C
pathway is stimulated by protein S7'8 and that factor Xa
protects factor Va against inactivation by APC.:'zo'zt (i-
netic analysisl8 of the effects of factor Xa and protein S
on time courses of normal factor Va inactivation sug-
gests that factor Xa specifically inhibits the rapid phase
of inactivation that is cleavage at Args06 and that protein
S accelerates the second phase of inactivation that is as-
sociated with cleavage at ^ 419306. The fact that factor Xa
does not protect factor Vur",u"n and that protein S acceler-
ates its inactivation more than 20-fold18 confirms that
the target site of protein S is Arg:00 and that factor Xa
specifically inhibits cleavage at Args06. This suggests
that in the presence of factor Xa and protein S factor Va
and factor Vur",u"n will be inactivated mainly via path-
way 2 (Fig. 3), which diminishes the differences in sen-
sitivity of normal factor Va and factor Vur"ro.n for APC
and may explain why APC resistance is only a mild risk
factor for venous thrombosis.
SGREENING FOR THE FACTOR V.'o."
MUTATION BY MEASURING THE
EFFECT OF APC ON THROMBIN
GENERATION IN PLASMA
On the basis of the information obtained on the
down-regulation of factor Va cofactor activity by APC in
model systems, we have developed two new methods for
the screening of APC resistance.22-2a In one of the ac-
companying papers in this issue Michiels and Hamuly6k
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FlG. 3, Pathways of factor Va and factor Valeiden i activation by APC (reprinted with permission).
present the clinical application of our prothrombinase-
based assay. In this article we will discuss the possibility
to screen for APC resistance by measuring the effect of
APC on the thrombin potential, a valuable diagnostic pa-
rameter introduced by Hemker and co-workers some 10
yearc ago.2s,26
When coagulation in a plasma sample is initiated
with thromboplastin and thrombin formation is quanti-
tated with a thrombin-specific chromogenic substrate,
one obtains the so-called thrombin generation curve
(Fig. a). The rising part of this curve probes the activa-
tion and in some cases also the inactivation of the coagu-
lation factors that are involved in prothrombin activa-
tion. The descending part of the curve mainly reflects the
inhibition of thrombin by plasma protease inhibitors,
particularly antithrombin and a-2 macroglobulin (a-2M).
J J  I
o2M-Thrombin
0 5 1 0 1 5
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FlG. 4. The thrombin generation curve.
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Because the cr-2M-thrombin (cr-2M-IIa) complex is still
active on chromogenic substrates, the curve ends with a
constant, residual level of amidolytic activity. Using the
rate constant of inhibition of thrombin by cr-2M, it is
possible to calculate the amount of o-2M-IIa present at
any moment and correct the thrombin generation curve
for the contribution of this complex.z5 After this correc-
tion, one obtains the amount of free thrombin present in
clotting plasma as a function of time. The surface under
this curve is defined as the endogenous thrombin poten-
tial (ETP), which has a value of 382 nM.min -r 52 (SD)
in plasma samples of normal individuals.26
It appears that thrombin generation in normal plasma
canbe almostcompletely abolishedbyAPC (Fig. 5A). The
middle panel of this figure (Fig. 58) shows the effect of the
same APC concentration on thrombin generation in
plasma of a heterozygous calrrier of factor Vl"id"n. It is obvi-
ous that thrombin generation is resistant towards APC and
that approximately two to three times more thrombin is
formed than in normal plasma. Thrombin generation in
plasma of a homozygous carrier of factor Vr",*n is even
less affected by APC (Fig. 5C). Visual inspection of the
thrombin generation curves indicates that APC decreases
the thrombin potential in this plasma by less than 507o.
To quantitate the effect ofAPC on thrombin genera-
tion we defined an APC sensitivity ratio (APC-sr) that is
equal to the ratio of thrombin potentials determined in
the presence and absence of APC. Because the final level
of e-2M-IIa appears to be proportional to theETP,23'27'28
values of the APC-sr calculated from the ETP are the
same as those calculated from final levels of cr-2M-IIa
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FlG. 6. n-APC-sr of normal individuals, heterozygous and ho-
mozygous carriers of factor VL"id"n determined by measuring the
effect of APC on the endogenous thrombin potential. Data from
Nicolaes et al23 and Rosing et a|.33
nApC_sr - ( orM_l Ia*o../orM_ITa_orc)prurru rnrpt./
(ctrM-IIa*ora/crrM-IIa_ora)nomal plasma pool.
It should be emphasized that due to the calculation pro-
cedure, nAPC-sr determined with the thrombin potential
method shows trends that are the reverse of those ob-
tained with assays based on the determination of the
effect of APC on the activated partial thromboplastin
time (APTT).2e Thus, with the thrombin potential method,
normal plasmas will give nAPC-sr - 1, while APC-resis-
tant plasmas will give higher nAPC-sr than normal
plasma.
Figure 6 shows the result of a determination of the
nAPC-sr with the thrombin potential method of a large
number of plasma samples from healthy individuals and
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FlG. 5. Effect of APC on thrombin generaiion in plasma.
Thrombin generation was initiated in normal plasma (A), in
plasma of a heterozygous (B), or homozygous carrier of factor
V.",o"n (C) with a phospholipid/CaOlr/tissue factor mixture either
in the abensce (A) or presence (O) of APC. Thrombin formation
was determined with the chromogenic substrate D-Phe-
(pipecolyl)-Arg-pNA (52238). The amidolytic activity was cor-
rected for the contribution of the a-2M-lla complex. Further de-
tails are given in Nicolaes et al23 (reprinted with permission).
determined after 15-20 min. To increase day-to-day re-
producibility, data were expressed as normalized APC-
sensitivity ratios (nAPC-sr) by dividing the APC-sr
through the same ratio determined in a normal pooled
plasma. Hence, the n-APC-sr can be also calculated ac-
cording the formula:
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FlG. 7. Effect of OC therapy on n-APC-sr determined by mea-
suring the effect of APC on the endogenous thrombin potential.
The populations are: women who do not use OC (no OC),
women who use second-generation monophasic OC (MP2),
women who use third-generation monophasic OC (MP3), and
heterozygous female carriers of the factor Vleiden mutation who
do not use OC (FVL"id"n). Data from Rosing et a1.33
MP3 Heterozygous
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TABLE 1. APC Sensitivity Ratios and Risks of Venous
Thrombosis of OC Users and Heterozygous and Homozygous
Carriers of Factor V
333
Women
nAPC-sra
(95-95 percentile) Risk Increase
N o F V - . .
Letoen
N o F V . . .
Heterozygous FVr",o"n
Heterozygous FVr",o.n
Homozygous FVr",o"n
no OC
MP3
no OC
OC
no OC
0.8't-2.t5
1.9 r -3.88
2.09-6.60
4.53-6.45
3.9r-6.02
6-8b
7c
30-504e
>50f
53
40
l7
6
5
Data from 
"Rosing et a1,33 bWHO,36 cKoster et al,az dVandenbroucke et a1,43 eBloe-
menkamp et al,aa and iRosendaal et a1.a5
MP3, users of third generation monophasic OC.
from heterozygous and homozygous carriers of factor
Vr",o.o. It appears that the majority of the normal plasma
samples indeed had a nAPC-sr around 1 and that carriers
of the factor Vr",u"n mutation had nAPC-sr higher than2.
It was, however, not possible to discriminate fully normal
individuals from carriers of factor Vr",o"n because there
was some overlap between the nAPC-sr of these popula-
tions.
OC THERAPY AND ACQUIRED
APC RESISTANCE
The data presented above indicate that the ETP test
is not 1007o decisive like DNA analysis,3o a prothrombi-
nase-based assay,22'24 or an APTT-based test performed
in factor V-deficient plasm4:t':z' and one may question
the usefulness of APC-resistance tests that arc not 1007o
specific for the factor Vr".o"n mutation. We feel, how-
ever, that a functional test that is influenced by other
plasma components and hence yields a distribution of
APC-sr may contain valuable information regarding the
prothrombotic status of an individual. This can be illus-
trated on the basis of an extensive study of plasmas of
women using oral contraceptives (OC), which shows
that APC-sr determined with the ETP method are
strongly influenced by the use of OC and may be a good
parameter to investigate the effects of OC on the hemo-
:Iatic process.33
During the development of our assay, we observed
--i-rt 
.Afflgn who used OC had significantly higherAPC-
sx::;t \lomen who did not take oc. that is. were less
sen-iru\. to APC and hence acquired APC resistant
t Fig- - r. Ii is interesting to note that the APC-sr of plas-
mas of \romen s'ho take third-generation monophasic
Qf ssnreinins deso_sestrel or gestodene were signifi-
cantlv higher than those of women who used second-
generation monophasic OC containing levonorgestrel of
lynestrenol and did not significantly differ from the
APC-sr of heterozr'-sous APC-resistant women who were
not using OC.
These obsen-ations indicate that OC therapy in-
duces acquired APC resistance, the extent of which de-
pends on the kind of OC used. Acquired APC resistance
may well explain the higher risk of thrombotic disease of
women taking OC:+ and the different risks reported for
women who use second- or third-generation OC.3s 38
This proposal is supported by the fact that there appears
to be a good correlation between the values of the
nAPC-sr determined with the ETP method and the in-
creased risk for deep-vein thrombosis in women who use
third-generation OC and in caffiers of factor Vr",o"n
(Table 1). During our study we identified six women
who were using OC and who were also heterozygous
carriers of the factor V, .. mutation. These women had
APC-sr that are nor-ui"t'f"LUrerved for individuals that
are homozygous for the factor Vr",o"n mutation and who
do not use OC. The fact that the risk increase for venous
thrombosis of heterozygous pill users and homozygous
nonusers are similar further supports our proposal that
the increased incidence of venous thrombosis in congen-
ital APC-resistant individuals and in women using OC
may originate from a defect in the same physiological
pathway.
Unfortunately, we have as yet no information about
the molecular mechanism by which OC induce acquired
APC resistance. In this respect we would like to empha-
size that also according to the APTT-based assay, the use
of OC is associated with acquired APC resistance.3e 4l
The effects of OC on APC-sr determined with the APTT-
based method are, however, much less pronounced and
as yet no significant differences were reported between
APC-sr determined with this method in plasma of users
of second- and third-generation OC. Because the major
difference between the APTT- and ETP-based assays is
the fact that in the APTT coagulation is initiated via the
intrinsic pathway and in the ETP method is initiated via
the extrinsic pathway, this may indicate that the major
point of attack of OC likely has to be sought in the activ-
ity or regulation of extrinsic coagulation pathway.
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